- Stocks
- Healthcare
- NASDAQ: CYTK

Price (delayed)

$50.17

Market cap

$4.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.55

Enterprise value

$4.95B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by

Cytokinetics's gross profit has soared by 162% YoY and by 132% from the previous quarter

The revenue has soared by 162% year-on-year and by 132% since the previous quarter

Cytokinetics's quick ratio has soared by 54% YoY but it has decreased by 4.3% from the previous quarter

The net income is down by 39% year-on-year but it is up by 16% since the previous quarter

The debt has increased by 36% YoY

CYTK's equity is down by 4.2% since the previous quarter

What are the main financial stats of CYTK

Market
Valuations
Earnings

Shares outstanding

94.14M

Market cap

$4.72B

Enterprise value

$4.95B

Price to earnings (P/E)

N/A

Price to book (P/B)

38.57

Price to sales (P/S)

28.46

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

32.77

Revenue

$151.15M

EBIT

-$201.99M

EBITDA

-$198.05M

Free cash flow

-$236.05M

Per share
Balance sheet
Liquidity

EPS

-$2.55

Free cash flow per share

-$2.75

Book value per share

$1.3

Revenue per share

$1.76

TBVPS

$9

Total assets

$771.72M

Total liabilities

$660.3M

Debt

$324.05M

Equity

$111.41M

Working capital

$535.41M

Debt to equity

2.91

Current ratio

9.01

Quick ratio

8.8

Net debt/EBITDA

-1.16

Margins
Efficiency
Dividend

EBITDA margin

-131%

Gross margin

100%

Net margin

-142.8%

Operating margin

-118.8%

Return on assets

-26.2%

Return on equity

-119.9%

Return on invested capital

-21.4%

Return on capital employed

-28.7%

Return on sales

-133.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Cytokinetics stock price performed over time

Intraday

-0.26%

1 week

-6.29%

1 month

23.88%

1 year

56.05%

YTD

10.07%

QTD

27.69%

How have Cytokinetics's revenue and profit performed over time

Revenue

$151.15M

Gross profit

$151.15M

Operating income

-$179.64M

Net income

-$215.92M

Gross margin

100%

Net margin

-142.8%

Cytokinetics's gross profit has soared by 162% YoY and by 132% from the previous quarter

The revenue has soared by 162% year-on-year and by 132% since the previous quarter

Cytokinetics's operating margin has soared by 65% from the previous quarter and by 46% YoY

The net margin has soared by 64% from the previous quarter and by 47% YoY

What is Cytokinetics's growth rate over time

What is Cytokinetics stock price valuation

P/E

N/A

P/B

38.57

P/S

28.46

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

32.77

The EPS has grown by 20% from the previous quarter but it has contracted by 16% YoY

The price to book (P/B) is 82% higher than the last 4 quarters average of 21.2

CYTK's equity is down by 4.2% since the previous quarter

The revenue has soared by 162% year-on-year and by 132% since the previous quarter

CYTK's P/S is 55% below its last 4 quarters average of 63.3 and 15% below its 5-year quarterly average of 33.7

How efficient is Cytokinetics business performance

The ROS has soared by 64% from the previous quarter and by 45% YoY

The return on equity is up by 33% year-on-year and by 27% since the previous quarter

The company's return on assets rose by 22% QoQ and by 10% YoY

CYTK's return on invested capital is up by 22% since the previous quarter and by 9% year-on-year

What is CYTK's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CYTK.

How did Cytokinetics financials performed over time

The total assets is 17% greater than the total liabilities

Cytokinetics's quick ratio has soared by 54% YoY but it has decreased by 4.3% from the previous quarter

The company's current ratio has surged by 53% YoY but it fell by 3.4% QoQ

The debt is 191% more than the equity

Cytokinetics's debt to equity has shrunk by 80% YoY but it has increased by 5% QoQ

The debt has increased by 36% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.